Ads
related to: second line treatment for hcc tumor marker- Unresectable HCC Therapy
Combination Treatment For
Unresectable HCC. Visit Site.
- View The Dosing Regimen
See The Dosing Schedule For A
Unresectable HCC Treatment
- Clinical Study Data
View Data For An Unresectable
Hepatocellular Carcinoma Treatment.
- Official Oncologist Site
Visit Official HCP Site To Learn
About An Immunotherapy Option.
- Safety Info From A Study
See Adverse Reaction Data For A
First-Line Unresectable HCC Therapy
- Connect With A Rep
Have Questions? Find Your Local
Representative To Get Answers.
- Unresectable HCC Therapy
Search results
Results From The WOW.Com Content Network
In 2007, sorafenib, an oral multikinase inhibitor, was the first systemic agent approved for first-line treatment of advanced HCC. [76] Trials have found modest improvement in overall survival: 10.7 months vs 7.9 months and 6.5 months vs 4.2 months. [77] [76] The most common side effects of Sorafenib include a hand-foot skin reaction and ...
Micrograph showing a PD-L1 positive non-small cell lung carcinoma. PD-L1 immunostain. As of 2019, pembrolizumab is used via intravenous infusion to treat inoperable or metastatic melanoma, metastatic non-small cell lung cancer (NSCLC) in certain situations, as a first-line treatment for metastatic bladder cancer in patients who cannot receive cisplatin-based chemotherapy and have high levels ...
For example, tumor markers like Ki-67 can be used to choose form of treatment or in prognostics but are not useful to give a diagnosis, while other tumor markers have the opposite functionality. Therefore it's important to follow the guidelines of the specific tumor marker. Tumor markers are mainly used in clinical medicine to support a ...
The most frequent liver cancer, accounting for approximately 75% of all primary liver cancers, is hepatocellular carcinoma (HCC). [15] HCC is a cancer formed by liver cells, known as hepatocytes, that become malignant. In terms of cancer deaths, worldwide HCC is considered the 3rd most common cause of cancer mortalities. [16]
Mantle cell lymphoma (MCL) is a type of non-Hodgkin's lymphoma, comprising about 6% of cases. [1] [2] It is named for the mantle zone of the lymph nodes where it develops.[3] [4] The term 'mantle cell lymphoma' was first adopted by Raffeld and Jaffe in 1991.
The cancer stem cell model, also known as the Hierarchical Model proposes that tumors are hierarchically organized (CSCs lying at the apex [6] (Fig. 3).) Within the cancer population of the tumors there are cancer stem cells (CSC) that are tumorigenic cells and are biologically distinct from other subpopulations [7] They have two defining features: their long-term ability to self-renew and ...
Ads
related to: second line treatment for hcc tumor marker